Related Experiment Video

Updated: Sep 12, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

Preserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol

Kevan C Herold¹, Colin M Dayan², Lucienne Chatenoud³

¹Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA. Kevan.herold@yale.edu.

|September 10, 2026

Abstract

Aims/Hypothesis:

In the PROTECT randomised trial, teplizumab demonstrated significantly greater beta cell function preservation vs placebo in the intent-to-treat (ITT) population. Analyses of the pre-specified per-protocol (PP) population and PP subgroups are presented to further evaluate the efficacy of teplizumab.

Methods:

Participants aged 8-17 years with stage 3 type 1 diabetes with a peak stimulated C-peptide level ≥0.2 nmol/l (ITT population: N=328) were randomised 2:1 to receive two 12-day courses of teplizumab or placebo intravenously. Participants with <80% treatment adherence, who took prohibited medication, received incorrect study treatment or were pregnant were excluded from the PP population. Subgroup analyses were based on the presence of HLA-DR3 or HLA-DR4 and the type of baseline type 1 diabetes autoantibodies.

Results:

The PP population comprised 275 participants (teplizumab, n=180; placebo, n=95). At week 78, the primary endpoint of the least squares (LS) mean difference in change of stimulated C-peptide concentration from baseline between teplizumab and placebo was 0.14 nmol/l (95% CI 0.10, 0.18; p<0.001). At week 78, teplizumab treatment significantly reduced the exogenous insulin dose (LS mean difference -0.17 U kg^-1 day^-1; 95% CI -0.26, -0.08; p<0.001) and increased the time in range (TIR) (LS mean difference 6.17%; 95% CI 0.13, 12.2; p<0.05) vs placebo. In subgroup analyses, treatment with teplizumab resulted in higher C-peptide levels compared with placebo, regardless of HLA-DR3/HLA-DR4 presence or baseline type 1 diabetes autoantibodies.

Conclusions/Interpretation:

Teplizumab treatment per protocol led to greater beta cell function preservation, greater TIR and lower exogenous insulin use compared with placebo. Beta cell function preservation was maintained irrespective of HLA subtype or the presence of type 1 diabetes autoantibodies.

Trial Registration:

ClinicalTrials.gov NCT03875729 FUNDING: The study was funded by Provention Bio, a Sanofi company.

Keywords:

Clinical immunology Diabetes in childhood Prediction and prevention of type 1 diabetes

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

Optimized Protocol for Generating Functional Pancreatic Insulin-secreting Cells from Human Pluripotent Stem Cells

Optimized Protocol for Generating Functional Pancreatic Insulin-secreting Cells from Human Pluripotent Stem Cells

Published on: February 2, 2024

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Articles linked to this work by shared authors, journal, and citation graph.

Phylogenomic analyses of the Austral podocarps (Podocarpus: Podocarpaceae) support hybrid ancestry of a New Zealand species.

Molecular phylogenetics and evolution·2026

Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases.

Journal of clinical immunology·2026

A surviving beta cell subpopulation enriched in patients with T1D.

bioRxiv : the preprint server for biology·2026

Effect of Poly-γ-glutamic Acid on Kinetics of Enamel Demineralization in vitro at pH 4.0, 4.5 and 5.0.

Calcified tissue international·2026

Characterisation of a New Bioactive Glass-Containing Fluoride Varnish.

Materials (Basel, Switzerland)·2026

Serial Dried Blood Spot C-Peptide Sampling, but Not Urine C-Peptide-to-Creatinine Ratio, Detects Early Preservation of β-Cell Function in New-Onset Type 1 Diabetes: Experience From the USTEKID Trial.

Diabetes care·2026

See all related articles